ACAA gives investors a real trust account, a health-and-technology sponsor story, and almost no operating company to analyze. The question is whether that blank check becomes a disciplined de-SPAC or another dilution machine.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
